View in EDS HTML Full Text PDF Full Text

An introduction to the Marburg virus vaccine consortium, MARVAC.

Saved in:
Bibliographic Details
Title: An introduction to the Marburg virus vaccine consortium, MARVAC.
Authors: Cross RW; Galveston National Laboratory, and Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, United States of America., Longini IM; Department of Biostatistics, University of Florida, Gainesville, Florida, United States of America., Becker S; Institute for Virology, Philipps-Universität Marburg, Marburg, Germany., Bok K; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America., Boucher D; U.S. COVID-19 Response at U.S. Department of Health and Human Services, Washington, DC, United States of America., Carroll MW; Pandemic Sciences Institute, Nuffield Department of Medicine, Oxford University, United Kingdom., Díaz JV; World Health Organization, Geneva, Switzerland., Dowling WE; Coalition for Epidemic Preparedness Innovations (CEPI), Washington, Washington, DC, United States of America., Draghia-Akli R; Johnson & Johnson-Global Public Health Research and Development, Spring House, Pennsylvania, United States of America., Duworko JT; Partnership for Research on Infectious Diseases in Liberia, Monrovia, Liberia., Dye JM; Virology Division, United States Army Medical Research Institute of Infectious Diseases, Frederick, Maryland, United States of America., Egan MA; Auro Vaccines, Pearl River, New York, United States of America., Fast P; IAVI, New York, New York, United States of America., Finan A; Sabin vaccine Institute, Washington, DC, United States of America., Finch C; Sabin vaccine Institute, Washington, DC, United States of America., Fleming TR; University of Washington, Seattle, Washington, United States of America., Fusco J; Public Health Vaccines, Cambridge, Massachusetts, United States of America., Geisbert TW; Galveston National Laboratory, and Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, United States of America., Griffiths A; National Emerging Infectious Diseases Laboratories, Boston University School of Medicine, Boston, Maryland, United States of America., Günther S; Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany., Hensley LE; Integrated Research Facility, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, Maryland, United States of America., Honko A; National Emerging Infectious Diseases Laboratories, Boston University School of Medicine, Boston, Maryland, United States of America., Hunegnaw R; Immune Biology of Retroviral Infection Section, Vaccine Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America., Jakubik J; Sabin vaccine Institute, Washington, DC, United States of America., Ledgerwood J; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America., Luhn K; Janssen Vaccines & Prevention, Leiden, the Netherlands., Matassov D; Auro Vaccines, Pearl River, New York, United States of America., Meshulam J; Auro Vaccines, Pearl River, New York, United States of America., Nelson EV; Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany., Parks CL; IAVI, New York, New York, United States of America., Rustomjee R; Sabin vaccine Institute, Washington, DC, United States of America., Safronetz D; Zoonotic Diseases and Special Pathogens Division, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada., Schwartz LM; World Health Organization, Geneva, Switzerland., Smith D; Bacterial and Combination Vaccines, Public Health Agency of Canada, Ottawa, Ontario, Canada., Smock P; Sabin vaccine Institute, Washington, DC, United States of America., Sow Y; Collaborative Clinical Research Branch, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, United States of America., Spiropoulou CF; Viral Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America., Sullivan NJ; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America., Warfield KL; Emergent BioSolutions, Gaithersburg, Maryland, United States of America., Wolfe D; Bacterial and Combination Vaccines, Public Health Agency of Canada, Ottawa, Ontario, Canada., Woolsey C; Galveston National Laboratory, and Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, United States of America., Zahn R; Janssen Vaccines & Prevention, Leiden, the Netherlands., Henao-Restrepo AM; World Health Organization, Geneva, Switzerland., Muñoz-Fontela C; Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany., Marzi A; Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, United States of America.
Source: PLoS pathogens [PLoS Pathog] 2022 Oct 13; Vol. 18 (10), pp. e1010805. Date of Electronic Publication: 2022 Oct 13 (Print Publication: 2022).
Publication Type: Journal Article; Research Support, N.I.H., Intramural; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
Journal Info: Publisher: Public Library of Science Country of Publication: United States NLM ID: 101238921 Publication Model: eCollection Cited Medium: Internet ISSN: 1553-7374 (Electronic) Linking ISSN: 15537366 NLM ISO Abbreviation: PLoS Pathog Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Description
ISSN:1553-7374
DOI:10.1371/journal.ppat.1010805